Literature DB >> 1370092

Identification of VP7 epitopes associated with protection against human rotavirus illness or shedding in volunteers.

K Y Green1, A Z Kapikian.   

Abstract

Sera from 17 of 18 adult volunteers challenged with a virulent serotype 1 rotavirus strain (D) were examined for prechallenge antibody levels against several well-defined rotavirus VP7 and VP4 neutralization epitopes by a competitive epitope-blocking immunoassay (EBA) in order to determine whether correlates of resistance to diarrheal illness could be identified. The presence of prechallenge serum antibody at a titer of greater than or equal to 1:20 that blocked the binding of a serotype 1 VP7-specific monoclonal antibody (designated 2C9) that maps to amino acid residue 94 in antigenic site A on the serotype 1 VP7 was significantly associated with resistance to illness or shedding (P less than 0.001) or illness and shedding (P less than 0.01) following challenge with the serotype 1 virus. In addition, an EBA antibody titer of greater than or equal to 1:20 in prechallenge serum against a serotype 3 VP7-specific epitope (defined by monoclonal antibody 954/159) that maps to amino acid 94 on the serotype 3 VP7 was also significantly associated with resistance to illness or shedding (P = 0.02), with a trend for protection against illness and shedding. A trend was also noted between the presence of EBA antibody against a cross-reactive VP4 epitope common to many human rotavirus strains, including the challenge virus, or a rhesus monkey rotavirus strain-specific VP4 antigenic site, and resistance to illness or shedding. These data confirm that the presence of serum antibody correlates with resistance to rotavirus illness or shedding but, in addition, demonstrate the association of antibody to a specific epitope with resistance to illness or shedding. These data also suggest that antigenic site A on the rotavirus VP7, composed of amino acids 87 to 96, may be involved in the formation of a major protective epitope. Further study of the role of this epitope in the development of homotypic and heterotypic immunity to rotaviruses following natural or vaccine-induced infection may be important in the development of strategies for control of rotavirus diarrheal disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1370092      PMCID: PMC238315     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

Review 1.  Rotavirus: the major etiologic agent of severe infantile diarrhea may be controllable by a "Jennerian" approach to vaccination.

Authors:  A Z Kapikian; J Flores; Y Hoshino; R I Glass; K Midthun; M Gorziglia; R M Chanock
Journal:  J Infect Dis       Date:  1986-05       Impact factor: 5.226

2.  Safety and immunogenicity of live attenuated rhesus monkey rotavirus vaccine.

Authors:  C Christy; H P Madore; J J Treaner; K Pray; A Z Kapikian; R M Chanock; R Dolin
Journal:  J Infect Dis       Date:  1986-12       Impact factor: 5.226

3.  Preliminary evaluation of the efficacy of rhesus rotavirus vaccine strain MMU 18006 in young children.

Authors:  M B Rennels; G A Losonsky; M M Levine; A Z Kapikian
Journal:  Pediatr Infect Dis       Date:  1986 Sep-Oct

4.  Antigenic characterization of human and animal rotaviruses by immune adherence hemagglutination assay (IAHA): evidence for distinctness of IAHA and neutralization antigens.

Authors:  A Z Kapikian; W L Cline; H B Greenberg; R G Wyatt; A R Kalica; C E Banks; H D James; J Flores; R M Chanock
Journal:  Infect Immun       Date:  1981-08       Impact factor: 3.441

5.  Live attenuated oral rotavirus vaccine.

Authors:  Y D Senturia; C S Peckham; M Cordery; I A Chrystie; J E Banatvala; F E André
Journal:  Lancet       Date:  1987-11-07       Impact factor: 79.321

6.  Studies in volunteers with human rotaviruses.

Authors:  A Z Kapikian; R G Wyatt; M M Levine; R E Black; H B Greenberg; J Flores; A R Kalica; Y Hoshino; R M Chanock
Journal:  Dev Biol Stand       Date:  1983

7.  Oral administration of human rotavirus to volunteers: induction of illness and correlates of resistance.

Authors:  A Z Kapikian; R G Wyatt; M M Levine; R H Yolken; D H VanKirk; R Dolin; H B Greenberg; R M Chanock
Journal:  J Infect Dis       Date:  1983-01       Impact factor: 5.226

8.  Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine.

Authors:  T Vesikari; E Isolauri; E D'Hondt; A Delem; F E André; G Zissis
Journal:  Lancet       Date:  1984-05-05       Impact factor: 79.321

9.  Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants.

Authors:  P Hanlon; L Hanlon; V Marsh; P Byass; F Shenton; M Hassan-King; O Jobe; H Sillah; R Hayes; B H M'Boge
Journal:  Lancet       Date:  1987-06-13       Impact factor: 79.321

10.  Protective effect of naturally acquired homotypic and heterotypic rotavirus antibodies.

Authors:  S Chiba; T Yokoyama; S Nakata; Y Morita; T Urasawa; K Taniguchi; S Urasawa; T Nakao
Journal:  Lancet       Date:  1986-08-23       Impact factor: 79.321

View more
  13 in total

1.  Heterogeneity and temporal dynamics of evolution of G1 human rotaviruses in a settled population.

Authors:  Serenella Arista; Giovanni M Giammanco; Simona De Grazia; Stefania Ramirez; Concetta Lo Biundo; Claudia Colomba; Antonio Cascio; Vito Martella
Journal:  J Virol       Date:  2006-08-23       Impact factor: 5.103

2.  Serotype specificity of the neutralizing-antibody response induced by the individual surface proteins of rotavirus in natural infections of young children.

Authors:  G Menchaca; L Padilla-Noriega; M Méndez-Toss; J F Contreras; F I Puerto; H Guiscafré; F Mota; I Herrera; R Cedillo; O Muñoz; R Ward; Y Hoshino; S López; C F Arias
Journal:  Clin Diagn Lab Immunol       Date:  1998-05

3.  Divergence of VP7 genes of G1 rotaviruses isolated from infants vaccinated with reassortant rhesus rotaviruses.

Authors:  Q Jin; R L Ward; D R Knowlton; Y B Gabbay; A C Linhares; R Rappaport; P A Woods; R I Glass; J R Gentsch
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

Review 4.  Rotavirus vaccines: an overview.

Authors:  K Midthun; A Z Kapikian
Journal:  Clin Microbiol Rev       Date:  1996-07       Impact factor: 26.132

5.  Molecular Analysis of VP7 Gene of Rotavirus G1 Strains Isolated from North India.

Authors:  Swapnil Jain; Jitendraa Vashistt; Kanika Gupta; Ashok Kumar; Harish Changotra
Journal:  Curr Microbiol       Date:  2016-08-26       Impact factor: 2.188

6.  Epidemiology of symptomatic human rotaviruses in Bangalore and Mysore, India, from 1988 to 1994 as determined by electropherotype, subgroup and serotype analysis.

Authors:  S Aijaz; K Gowda; H V Jagannath; R R Reddy; P P Maiya; R L Ward; H B Greenberg; M Raju; A Babu; C D Rao
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

7.  Resistance to rotavirus infection in adult volunteers challenged with a virulent G1P1A[8] virus correlated with serum immunoglobulin G antibodies to homotypic viral proteins 7 and 4.

Authors:  Lijuan Yuan; Shinjiro Honma; Inyoung Kim; Albert Z Kapikian; Yasutaka Hoshino
Journal:  J Infect Dis       Date:  2009-11-01       Impact factor: 5.226

8.  The VP7 outer capsid protein of rotavirus induces polyclonal B-cell activation.

Authors:  Sarah E Blutt; Sue E Crawford; Kelly L Warfield; Dorothy E Lewis; Mary K Estes; Margaret E Conner
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

9.  Immunodominance of the VP4 neutralization protein of rotavirus in protective natural infections of young children.

Authors:  R L Ward; M M McNeal; D S Sander; H B Greenberg; D I Bernstein
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

10.  Prevalence of neutralizing antibodies against different rotavirus serotypes in children with severe rotavirus-induced diarrhea and their mothers.

Authors:  Pratibha G Ray; Shobhana D Kelkar
Journal:  Clin Diagn Lab Immunol       Date:  2004-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.